Asklepios BioPharma Launches New Biotech Actus Therapeutics Post author:Sam Post published:December 14, 2017 Post category:BioPharma Asklepios BioPharma is forming a new biotech portfolio company, Actus Therapeutics. Source: BioSpace You Might Also Like Former Biogen Exec Launches First Life Sciences Fund With $750 Million May 22, 2017 Oramed Granted Canadian Patent For GLP-1 Analog Capsule May 8, 2017 Berg Announces Appointment Of As Chief Operating Officer February 6, 2017
